La chaîne d'options affiche les données clés des options sur actions de Upexi à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Upexi..

Upexi (NASDAQ:UPXI) Stock, Chaîne d'Options

Upexi

Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via a Solana treasury strategy.

Upexi Inc

Wedbush analyst Alicia Reese maintains Logitech International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>) with a Outperform and raises the price target from $100 to $110.

News

Price Target

Analyst Ratings

LOGI

Wedbush Maintains Outperform on Logitech International, Raises Price Target to $110

Citigroup analyst Vikram Bagri maintains Oklo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) with a Neutral and raises the price target from $30 to $68.

OKLO

Citigroup Maintains Neutral on Oklo, Raises Price Target to $68

Wedbush analyst Alicia Reese maintains Beyond (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) with a Outperform and raises the price target from $10 to $13.

BYON

Wedbush Maintains Outperform on Beyond, Raises Price Target to $13

D.R. Horton Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) reported third-quarter financial results for fiscal 2025 before the market open on Tuesday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/07/b46538721/d-r-horton-inc-americas-builder-reports-fiscal-2025-third-quarter-earnings-and-declares-quarterly-">of the report</a>.
Q3 Earnings: D.R. Horton reported fiscal third-quarter revenue of $9.22 billion, beating analyst <a href="http://benzinga.com/quote/DHI/earnings">estimates</a> of $8.79 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The U.S. homebuilder reported third-quarter earnings of $3.36 per share, beating analyst estimates of $2.92 per share.
Total revenue was down 7% on a year-over-year basis. Home sales revenue also declined 7% to $8.6 billion after the company closed 23,160 homes in the quarter, down 4% year-over-year. Net sales orders came in at 23,071 during the period. 
&#8220;Our net sales orders in the&nbsp;third quarter&nbsp;were flat with the prior year quarter and increased&nbsp;3%&nbsp;sequentially. We closed more homes than the high end of our&nbsp;guidance&nbsp;range, while maintaining a home sales gross margin of&nbsp;21.8%,&#8221; said David Auld, executive chairman of D.R. Horton.
&#8220;Our tenured operators continue to respond to market conditions with discipline to drive traffic and incremental sales, while carefully balancing pace versus price to maximize returns.&#8221;
D.R. Horton said it repurchased 9.7 million shares of its common stock for $1.2 billion in the quarter and returned $122.4 million to shareholders via dividends. The company said it plans to repurchase a total of $4.2 billion to $4.4 billion of its common stock in fiscal 2025. 
Guidance: D.R. Horton narrowed its fiscal 2025 revenue guidance from a range of $33.3 billion to $34.8 billion to a new range of $33.7 billion to $34.2 billion versus estimates of $33.82 billion. 
The company expects to close a total of 85,000 to 85,500 homes during fiscal 2025. 
D.R. Horton executives will provide guidance for the fourth quarter on a conference call, which is set for 8:30 a.m. ET.
DHI Price Action: <a href="http://benzinga.com/quote/DHI">D.R. Horton shares</a> were up 7.5% at $141.11 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46478792/5-homebuilding-stocks-to-considering-selling-on-copper-tariff-threats">5 Homebuilding Stocks To Considering Selling On Copper Tariff Threats</a></li>
</ul>
Photo: JHVEPhoto/Shutterstock.com

Earnings

Guidance

Movers

D.R. Horton Stock Moves Higher After Homebuilder Beats Q3 Earnings Estimates

NTRP

NextTrip Partners With Jungle Creations To Accelerate Social Growth, Content Engagement, And Brand Awareness Of NextTrip's Travel And Lifestyle Media Brand, JOURNY

Blackstone Makes Majority Growth Investment In NetBrain, Valuing NetBrain At $750M

Citigroup analyst Ronald Josey maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and raises the price target from $225 to $265.

AMZN

Citigroup Maintains Buy on Amazon.com, Raises Price Target to $265

Wedbush analyst Alicia Reese reiterates Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) with a Outperform and maintains $210 price target.

Reiteration

Wedbush Reiterates Outperform on Electronic Arts, Maintains $210 Price Target

Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) reported better-than-expected second-quarter financial results and <a href="https://www.benzinga.com/quote/vz/earnings">raised guidance on Monday.</a>
Verizon posted adjusted earnings of $1.22 per share, beating market estimates of $1.19 per share. The company&#8217;s quarterly sales came in at $34.50 billion beating expectations of $33.57 billion.
Total Verizon Business revenues were $7.3 billion, down 0.3% Y/Y. Total Verizon Consumer revenue rose by 6.9% Y/Y to $26.6 billion. Consumer wireless retail postpaid churn was 1.12%, and wireless retail postpaid phone churn was 0.90%.
For FY25, Verizon reiterated a 2.0%-2.8% growth in wireless service revenue. It narrowed its adjusted EPS outlook from $4.59-$4.73 to $4.64-$4.73 versus the consensus of $4.68, driven by demand for its higher-tier plans as per the Reuters report.
Verizon shares gained 4% to close at $42.49 on Monday.
These analysts made changes to their price targets on Verizon following earnings announcement.
<ul class="wp-block-list">
<li>JP Morgan analyst Philip Cusick maintained Verizon with a Neutral and raised the price target from $47 to $49.</li>
<li>Morgan Stanley analyst Benjamin Swinburne maintained the stock with an Equal-Weight rating and raised the price target from $47 to $48.</li>
</ul>
Considering buying VZ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/VZ/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22090305/image-308-1024x583.png" alt="" class="wp-image-995410" style="width:608px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22090305/image-308-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22090305/image-308-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22090305/image-308-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22090305/image-308.png 1093w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46517205/top-2-financial-stocks-that-may-plunge-this-month">Top 2 Financial Stocks That May Plunge This Month</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

These Analysts Raise Their Forecasts On Verizon After Upbeat Q2 Results

Citigroup analyst Tyler Radke maintains Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) with a Buy and raises the price target from $605 to $613.

MSFT

Citigroup Maintains Buy on Microsoft, Raises Price Target to $613

NTHI

NeOnc Technologies Secures Sub-License Deal, Advancing $50M Strategic Partnership With Quazar

General

LCID

TSLA

Lucid Announces Access To Tesla Supercharger Network Will Be Available For All Lucid Air Models Beginning July 31, With A Lucid-approved Adapter

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust (SPY)
SPY is presently trading near our important level of 628.31. Bulls are targeting an initial advance to 629.56. If momentum persists above 629.56, we anticipate buyers driving prices toward our next key support at 631.10. Should buyers confidently defend 631.10 throughout regular session trading, look for a continuation upward to 631.96, with our ultimate bullish target for the day sitting at 632.80.&nbsp;
If bulls lose their grip at 628.31, sellers will aim for downside momentum, initially challenging the 627.25 level. Continued bearish pressure will put the 625.96 mark at risk. Breaking this level decisively could see SPY quickly trading down toward the strong support at 624.22. If selling intensifies dramatically, bears might reach our lowest target for the session at 622.67.
Invesco QQQ Trust Series 1 (QQQ)
The QQQ is currently trading near our pivotal level of 562.78. Bulls must firmly establish price action above this mark, subsequently securing 564.71 as reliable intraday support. Persistent bullish sentiment should then encourage further upside momentum, targeting the next resistance at 567.19. If today&#8217;s buying is robust, anticipate a stretch toward 570.57, with our top bullish objective for the QQQ standing at 573.87.&nbsp;
Should QQQ fail to hold 562.78 convincingly during market hours, bears will seize control and push downward aggressively, first testing the 561.03 area. If weakness persists, expect a deeper selloff toward 559.89. Continued bearish dominance could trigger further downside pressure toward the support at 558.17. A breach here opens the door to our lowest bearish target of the day at 557.16.
Apple Inc. (AAPL)
Apple is trading near our crucial price level of 212.75. Bulls should aim to maintain this support, driving the stock upward initially toward 214.06. Sustained buying could elevate Apple to the next upside hurdle at 215.38. If bullish participants decisively dominate today&#8217;s trading, our high-end bullish target of 217.01 becomes attainable.&nbsp;
If buyers fail to defend the critical level at 212.75, bearish sellers will quickly target 211.75 as their first destination. Continuation of selling momentum would bring Apple down to the next support zone at 210.87. A breakdown of that level might induce additional selling toward 210.12, with further weakness potentially reaching our lower bear target at 209.49.
Microsoft Corp. (MSFT)
Microsoft is currently trading near our highlighted level of 509.09. Bulls will first need to secure the area above 508.79, setting the stage for a move upward toward 510.99, which would then act as an intraday support. Holding firmly above 510.99 would position Microsoft for a bullish run toward 512.86, with sustained buyer participation likely pushing prices to our daily bullish target of 515.30.&nbsp;
If 509.09 is not maintained, expect bears to swiftly challenge the 507.92 mark. Breaking below this support will encourage additional downside pressure, targeting 506.37. Should selling intensify, the next bearish objective becomes 504.85, ultimately opening a path toward our lowest bearish target for the session at 503.48.
NVIDIA Corporation (NVDA)
NVIDIA is currently trading around our critical level of 169.72. Bulls must push the price higher initially to reclaim and firmly establish support at 170.76. Continued upward momentum would then open a pathway to the next resistance point at 172.13. Strong buying throughout the day could drive NVIDIA further upward toward 173.47, with our top bullish target today placed at 175.13.&nbsp;
If NVIDIA cannot hold above 169.72, expect bearish sellers to target a move lower initially toward 167.52. A breakdown here with notable selling volume could rapidly take prices down to 166.01. Further weakening could see bears testing 164.70, and continued downside momentum might ultimately push NVIDIA toward our daily bearish objective at 163.71.
Alphabet Inc Class A (GOOGL)
Alphabet is presently trading close to our significant level of 190.75. Bulls will first aim to firmly secure this area as intraday support, targeting a push higher toward resistance at 191.80. Strong bullish activity might then extend this rally to reach today&#8217;s ultimate bullish target of 193.67.&nbsp;
If buyers are unable to protect 190.75, sellers will likely take control and aggressively test support lower at 189.64. If bearish sentiment intensifies, expect the auction to continue downward toward 188.53. Under heavy selling pressure, Alphabet could fall toward our low-end bearish objective of 186.80.
Meta Platforms Inc (META)
Meta is currently trading near our key level of 714.32. Bulls will look to establish firm price strength above 717.03, setting up the opportunity for further advances toward 718.98. Continued bullish conviction should then lift Meta toward the next resistance level at 721.62, with potential for buyers to drive price action toward our bullish target at 724.27.&nbsp;
If Meta fails to maintain support at 714.32, sellers will immediately target a decline to the support level at 710.41. Continued bearish activity would encourage a further drop toward 707.95. Should this area fail to hold, increased selling might accelerate the move down toward our lowest bearish target of the session at 705.95.
Tesla Inc. (TSLA)
Tesla is currently trading around our significant price level of 328.57. Bulls should first target a move upward to 330.85, with continued buying momentum potentially lifting prices to the next resistance at 334.53. If market sentiment is strongly bullish today, Tesla may push higher toward 340.46, with our maximum bullish objective sitting at 342.71.&nbsp;
If the support level at 328.57 is compromised, anticipate sellers moving swiftly to test lower prices around 326.73. Additional bearish pressure would likely bring Tesla down further to 324.89. Failure at this level with intensified selling could prompt further downside to our daily bearish target of 323.50.
Final Word: Today&#8217;s economic calendar remains exceptionally sparse, continuing the trend of limited catalysts that could keep trading ranges tighter than usual. At 8:30 AM ET, the Philly Fed Non-Manufacturing Activity Index for July will be released, providing regional insights into service sector performance and potential shifts in business sentiment outside manufacturing.&nbsp;
Following at 10:00 AM ET, expect the Richmond Fed Manufacturing Index and Business Conditions report, offering a view into mid-Atlantic factory activity and broader operational trends that might subtly influence economic perceptions.&nbsp;
On the speaker front, Fed Chair Jerome Powell is set to appear at 8:30 AM ET. Given the ongoing blackout period ahead of policy meetings, comments on future rate decisions are improbable, though tensions with the Trump administration could prompt unconventional remarks. Additionally, voting member Fed Governor Michelle Bowman will speak at 1:00 PM ET, potentially touching on key issues without violating blackout norms. Approach the session with measured expectations, monitor for any surprises, and prioritize sound risk management. Good luck and trade safely!
Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga&#8217;s reporting and has not been edited for content or accuracy.
&#x2A;&#x2A;
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Equities

Broad U.S. Equity ETFs

Technicals

Opinion

Signals

How To Trade SPY, Top Tech Stocks Today Using Technical Analysis

Econ #s

Redbook: US Retail Sales First 2 Weeks Jul +5.2% vs Year Ago

8 analysts have expressed a variety of opinions on Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Jazz Pharmaceuticals, revealing an average target of $176.12, a high estimate of $202.00, and a low estimate of $147.00. Highlighting a 4.67% decrease, the current average has fallen from the previous average price target of $184.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1753189273_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Jazz Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$155.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$172.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$147.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$166.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Jazz Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Jazz Pharmaceuticals's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Jazz Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Jazz Pharmaceuticals analyst ratings.</a>
<h2>All You Need to Know About Jazz Pharmaceuticals</h2>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Unraveling the Financial Story of Jazz Pharmaceuticals</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Negative Revenue Trend: Examining Jazz Pharmaceuticals's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -0.46% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Jazz Pharmaceuticals's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -10.31%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Jazz Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -2.24%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.79%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.3, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

JAZZ

Where Jazz Pharmaceuticals Stands With Analysts

GM CFO On Conf Call Reportedly Says EV Policy Changes Will Have Minimal Impact on 2025 Results

Redbook: US Retail Sales +5.1% Week End Jul 19 YoY

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Criteo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRTO#NASDAQ">CRTO</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $43.1, a high estimate of $66.00, and a low estimate of $27.00. Experiencing a 17.75% decline, the current average is now lower than the previous average price target of $52.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1753189258_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Criteo by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Zgutowicz</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$42.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$42.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$27.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$36.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$49.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Alec Brondolo</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Alec Brondolo</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$66.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Ygal Arounian</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$47.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Criteo. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Criteo compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Criteo's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Criteo's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CRTO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Criteo analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Criteo</h2>
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
<h3>Criteo's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Criteo displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 0.31%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Communication Services sector.
Net Margin: Criteo's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.4%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Criteo's ROE stands out, surpassing industry averages. With an impressive ROE of 3.59%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Criteo's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.73% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.1.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CRTO

10 Analysts Have This To Say About Criteo

4 analysts have shared their evaluations of Stagwell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STGW#NASDAQ">STGW</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.34, a high estimate of $9.50, and a low estimate of $6.36. This current average represents a 4.25% decrease from the previous average price target of $8.71. 
<img src="https://www.benzinga.com/files/images/story/2025/1753189248_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Stagwell's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.36</td>
<td>$6.36</td>
</tr>
<tr>
<td>Steven Cahall</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Mark Zgutowicz</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Hold</td>
<td>$9.50</td>
<td>$9.50</td>
</tr>
<tr>
<td>Mark Zgutowicz</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$9.50</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Stagwell. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Stagwell compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Stagwell's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Stagwell's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STGW/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Stagwell analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Stagwell</h2>
Stagwell Inc is the challenger holding company built to transform marketing. It delivers scaled creative performance for the world's ambitious brands, connecting culture-moving creativity with a technology to harmonize the art and science of marketing. The company's segments include Integrated Agencies Network; Brand Performance Network; and Communications Network. It generates maximum revenue from the Integrated Agencies Network segment. Geographically, it derives a majority of its revenue from the United States.
<h3>Stagwell: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Challenges: Stagwell's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -2.73%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Communication Services sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -0.45%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.88%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Stagwell's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.07%, the company showcases efficient use of assets and strong financial health.
Debt Management: Stagwell's debt-to-equity ratio stands notably higher than the industry average, reaching 5.22. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

STGW

Breaking Down Stagwell: 4 Analysts Share Their Views

In the latest quarter, 10 analysts provided ratings for Magnite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Magnite and provided 12-month price targets. The average target is $22.7, accompanied by a high estimate of $39.00 and a low estimate of $18.00. This upward trend is apparent, with the current average reflecting a 18.11% increase from the previous average price target of $19.22.
<img src="https://www.benzinga.com/files/images/story/2025/1753189240_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Magnite among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Alec Brondolo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$39.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Eric Martinuzzi</td>
<td>Lake Street</td>
<td>Lowers</td>
<td>Buy</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Announces</td>
<td>Buy</td>
<td>$18.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Magnite. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Magnite compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Magnite's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Magnite's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MGNI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Magnite analyst ratings.</a>
<h2>Delving into Magnite's Background</h2>
Magnite Inc is one of the supply-side platform providers, or SSP, in online advertising. The firm generate its revenue from the programmatic sale of CTV ad inventory, from mobile online sites and apps, and the remaining from websites accessed via computer.
<h3>Unraveling the Financial Story of Magnite</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Magnite's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 4.32%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Communication Services sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Magnite's net margin is impressive, surpassing industry averages. With a net margin of -6.18%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Magnite's ROE stands out, surpassing industry averages. With an impressive ROE of -1.28%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Magnite's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.35% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Magnite's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.83.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MGNI

Demystifying Magnite: Insights From 10 Analyst Reviews

Press Releases

Upexi Joins Webull Corporate Connect Service Platform

Upexi CEO and CSO to Host Fireside Chat on Thursday, June 26th at 11:00 a.m. ET

Upexi's Chief Strategy Officer to Present at The ICR Conference Spotlight Series on June 20th

Nakamoto Holdings to Participate in ICR Conference Spotlight Series

Upexi Announces Intent to List SEC-Registered Shares On-Chain via Superstate's Opening Bell

Upexi, Inc. June 2025 Monthly Update

Upexi, Inc. Announces Pricing of $200 Million Concurrent Private Placement of Common Stock and Convertible Notes both Priced above the At-the-Market Price under Nasdaq Rules

Upexi Announces Closing of $50 Million Private Placement Equity Offering

Upexi Announces Closing of Approximately $150 Million Private Placement of Convertible Notes as Part of Previously Announced $200 Million Concurrent Offering

Upexi Grows Treasury to 1.819 Million SOL Worth $331 Million with a $58 Million Unrealized Gain in Under Three Months

CSE:HODL

NAKA

UPXI

AXIL Brands

BellRing Brands

Coty

Big Tree Cloud Holdings Limited - Ordinary Shares

Big Tree Cloud Holdings

Estee Lauder Companies, Inc. (The) Common Stock

Estee Lauder Cos

e.l.f. Beauty

Edgewell Personal Care Company Common Stock

Edgewell Personal Care

FitLife Brands

Herbalife

Honest Co

Interparfums

Kenvue

Lifevantage

Medifast

Nature's Sunshine Products, Inc. - Common Stock

Natures Sunshine Products

Natural Health Trends Corp. - Commn Stock

Natural Health Trends

Nu Skin Enterprises

Olaplex Hldgs

Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares

Paranovus Entertainment

Safety Shot

The Beauty Health Company - Class A Common Stock

Beauty Health

Unilever

Usana Health Sciences

Waldencast

Yatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary Shares

Yatsen Holding

Alliance Global Partners

EF Hutton

Comments

Upexi

Upexi (UPXI) Options

Upexi (NASDAQ:UPXI) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL